

Servier and BioLabs call for applications to join Spartners, the integrated incubator within the future Servier Research and Development Institute in Paris-Saclay

- **Spartners is a unique incubator in France that will provide all the conditions to stimulate therapeutic innovation and promote knowledge sharing.**
- **Applications open at Spartners for startups in the field of health and life sciences to become the first residents to join the site.**

Suresnes (France) and Cambridge, Massachusetts (USA), October 17th, 2022 – Servier and BioLabs Global announce the opening for applications at Spartners, the incubator located at the future Servier Research and Development Institute in Paris-Saclay scheduled to open in 2023.

The call for applications is aimed at young innovative companies in the field of health and life sciences that develop innovative concepts. Companies can apply via the form available on the website : <https://www.biolabs.io/apply-online>

Applications will be examined by a selection committee, composed of representatives from Servier and BioLabs, as well as experts representing key players in healthcare innovation: Medicen, France Biotech, the SATT network, and Bpifrance. Candidate companies can, if they wish, visit the incubator. For more information, you can visit the website: [BioLabs.io](https://www.biolabs.io)

Spartners, a unique place in France to stimulate therapeutic innovation and knowledge sharing

Olivier Nosjean, Director of Open Innovation at Servier, says: "Spartners is a perfect reflection of Servier's strong commitment to open innovation and its desire to bring together a variety of healthcare players to accelerate the discovery of therapeutic solutions to benefit patients. We are pleased to collaborate with BioLabs so that Spartners can be a place of synergy and innovation that will contribute to the dynamism of the healthcare ecosystem in France and Europe."



With a surface area of 1,850 m², Spartners has been designed to accommodate about 15 start-ups, or more than 100 scientists. The incubator will offer a unique-in-France combination of state-of-the-art space, services, and equipment that will allow startups to work independently while simultaneously benefiting from Servier's scientific and industrial expertise, as well as the world-class innovation ecosystem of the Paris-Saclay cluster.

A partnership with BioLabs to maximize the chances of success of start-ups

BioLabs is an international network of co-working facilities designed to help science-based start-ups grow rapidly with limited capital investment. BioLabs will manage the day-to-day operations of the site, as well as the provision of services and equipment.

Servier and BioLabs share a common motivation: to detect and support research projects that lead to therapeutic innovation.

Philippe Guédon, Director of the Spartners site adds: "The BioLabs guiding principle is to enable a community of entrepreneurs to accelerate the time-to-market of their solutions through premium offerings (fully equipped turnkey labs, EHS training, etc.). In addition to BioLabs' experience and know-how, our partnership with Servier will allow our residents to benefit from a real industrial environment within Spartners to further legitimize the science developed by the startups."

Johannes Fruehauf, CEO of BioLabs, states, "I am very pleased to join Servier in launching Spartners. This new site will offer scientists and entrepreneurs the opportunity to benefit from our partnership with Servier, a leading global pharmaceutical company, and access to BioLabs and our international network of shared laboratories. I look forward to meeting an extraordinary group of local, national and international entrepreneurs who will conduct their research at this exceptional site."

Servier media contact

Sonia Marques: presse@servier.com | Tel. +33 (0)1 55 72 40 21

About Servier

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,800 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth driver. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.7 billion in 2021.

More information on the new Group website: servier.com

Follow us on social media: [LinkedIn](#), [Facebook](#), [Twitter](#), [Instagram](#)

BioLabs media contact

Margaux Lesbats : margauxl@biolabs.io Tél : +33 6 73 32 85 30

About BioLabs

BioLabs designs and operates high-end life science labs and coworking spaces in the U.S. Europe and Japan in the heart of biotech innovation clusters. They offer beautifully designed coworking environments that pair fully equipped and supported lab, office, and event spaces with relevant programming and unparalleled access to capital and industry partners.

Thanks to the flexible terms and conditions of their facilities BioLabs enables the most promising life science innovators to work, collaborate, and attend events in a setting perfectly suited to their needs.

This fertile and supportive ecosystem allows start-ups to focus on innovation, not start-up operations, so they can quickly realize their scientific potential and achieve commercial success. Companies can start with a single bench and scale as they grow.

More information on the website: <https://www.biolabs.io>

Follow us on social networks: [LinkedIn](#), [Twitter](#)